GlassScriptPhysician profile
Mostafa Mazen
NPI 1497284731
$2,800.46
in general payments reported to CMS, 2019-2025
9 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,167 · 2024: $1,372 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Travel and Lodging: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.50 |
| Travel and Lodging | $867.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.08 | 2023-2025 | |
| Alcon Vision LLC | $651.33 | 2023-2025 | Hydrus Microstent, Voyager Dslt, Rhopressa |
| Glaukos Corporation | $473.92 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Sight Sciences, INC. | $161.32 | 2024-2025 | Omni Surgical System |
| Carl Zeiss Meditec USA, INC. | $115.23 | 2023 | Artevo 800 |
| Bausch & Lomb Americas INC. | $108.33 | 2024 | Miebo, Xiidra |
| New World Medical,INC. | $39.92 | 2023-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Mallinckrodt Hospital Products INC. | $35.60 | 2023 | Acthar |
| Thea Pharma INC. | $21.73 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mostafa Mazen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.